Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-8541A + Botensilimab + Balstilimab in Refractory Metastatic MSS-CRC
NCT06589440Phase 2Recruiting
- Sponsor
- Stingray Therapeutics
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vizenpistat in colorectal cancer (CRC), sponsored by Stingray Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
vizenpistat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06589440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589440.